

# World Journal of *Critical Care Medicine*

*World J Crit Care Med* 2017 May 4; 6(2): 91-139



**MINIREVIEWS**

- 91 Generalizable items of quantitative and qualitative cornerstones for personnel requirement of physicians in anesthesia

*Weiss M, Rossaint R, Iber T*

- 99 Severe trauma in the geriatric population

*Llompert-Pou JA, Pérez-Bárcena J, Chico-Fernández M, Sánchez-Casado M, Raurich JM*

**ORIGINAL ARTICLE****Basic Study**

- 107 Female gonadal hormone effects on microglial activation and functional outcomes in a mouse model of moderate traumatic brain injury

*Umeano O, Wang H, Dawson H, Lei B, Umeano A, Kernagis D, James ML*

**Retrospective Study**

- 116 Critical care management and intensive care unit outcomes following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy

*Kapoor S, Bassily-Marcus A, Alba Yunen R, Tabrizian P, Semoin S, Blankush J, Labow D, Oropello J, Manasia A, Kohli-Seth R*

**SYSTEMATIC REVIEWS**

- 124 Characteristics of postintensive care syndrome in survivors of pediatric critical illness: A systematic review

*Herrup EA, Wieczorek B, Kudchadkar SR*

**CASE REPORT**

- 135 Hemolytic uremic syndrome in adults: A case report

*Pérez-Cruz FG, Villa-Díaz P, Pintado-Delgado MC, Fernández\_Rodríguez ML, Blasco-Martínez A, Pérez-Fernández M*

**ABOUT COVER**

Editorial Board Member of *World Journal of Critical Care Medicine*, Dr. David C Willms, MD, Director, Critical Care, Sharp Memorial Hospital, San Diego, CA 92123, United States

**AIM AND SCOPE**

*World Journal of Critical Care Medicine (World J Crit Care Med, WJCCM, online ISSN 2220-3141, DOI: 10.5492)* is a peer-reviewed open access academic journal that aims to guide clinical practice and improve diagnostic and therapeutic skills of clinicians.

*WJCCM* covers topics concerning severe infection, shock and multiple organ dysfunction syndrome, infection and anti-infection treatment, acute respiratory distress syndrome and mechanical ventilation, acute kidney failure, continuous renal replacement therapy, rational nutrition and immunomodulation in critically ill patients, sedation and analgesia, cardiopulmonary cerebral resuscitation, fluid resuscitation and tissue perfusion, coagulant dysfunction, hemodynamic monitoring and circulatory support, ICU management and treatment control, and application of bronchofiberscopy in critically ill patients.

We encourage authors to submit their manuscripts to *WJCCM*. We will give priority to manuscripts that are supported by major national and international foundations and those that are of great clinical significance.

**INDEXING/ABSTRACTING**

*World Journal of Critical Care Medicine* is now indexed in PubMed, PubMed Central.

**FLYLEAF**

**I-III** Editorial Board

**EDITORS FOR THIS ISSUE**

**Responsible Assistant Editor:** *Xiang Li*  
**Responsible Electronic Editor:** *Ya-Jing Lu*  
**Proofing Editor-in-Chief:** *Lian-Sheng Ma*

**Responsible Science Editor:** *Fang-Fang Ji*  
**Proofing Editorial Office Director:** *Xiu-Xia Song*

**NAME OF JOURNAL**  
*World Journal of Critical Care Medicine*

**ISSN**  
 ISSN 2220-3141 (online)

**LAUNCH DATE**  
 February 4, 2012

**FREQUENCY**  
 Quarterly

**EDITOR-IN-CHIEF**  
**Bart Van Rompaey, BSc, MSc, PhD, Associate Professor, Nurse, Faculty** of Medicine and Health Sciences, Department of Nursing and midwifery, Centre for Research and Innovation in Care, University of Antwerp, Wilrijk 2610, Antwerp, Belgium

**EDITORIAL BOARD MEMBERS**  
 All editorial board members resources online at <http://www.wjnet.com/2220-3141/editorialboard.htm>

**EDITORIAL OFFICE**  
 Xiu-Xia Song, Director  
*World Journal of Critical Care Medicine*  
 Baishideng Publishing Group Inc  
 7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA  
 Telephone: +1-925-2238242  
 Fax: +1-925-2238243  
 E-mail: [editorialoffice@wjnet.com](mailto:editorialoffice@wjnet.com)  
 Help Desk: <http://www.f0publishing.com/helpdesk>  
<http://www.wjnet.com>

**PUBLISHER**  
 Baishideng Publishing Group Inc  
 7901 Stoneridge Drive,  
 Suite 501, Pleasanton, CA 94588, USA  
 Telephone: +1-925-223-8242  
 Fax: +1-925-223-8243  
 E-mail: [bpgoffice@wjnet.com](mailto:bpgoffice@wjnet.com)  
 Help Desk: <http://www.f0publishing.com/helpdesk>  
<http://www.wjnet.com>

**PUBLICATION DATE**  
 May 4, 2017

**COPYRIGHT**  
 © 2017 Baishideng Publishing Group Inc. Articles published by this Open-Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

**SPECIAL STATEMENT**  
 All articles published in journals owned by the Baishideng Publishing Group (BPG) represent the views and opinions of their authors, and not the views, opinions or policies of the BPG, except where otherwise explicitly indicated.

**INSTRUCTIONS TO AUTHORS**  
<http://www.wjnet.com/bpg/gerinfo/204>

**ONLINE SUBMISSION**  
<http://www.f0publishing.com>

## Basic Study

**Female gonadal hormone effects on microglial activation and functional outcomes in a mouse model of moderate traumatic brain injury**

Odera Umeano, Haichen Wang, Hana Dawson, Beilei Lei, Afoma Umeano, Dawn Kernagis, Michael L James

Odera Umeano, School of Medicine, Duke University, Durham, NC 27710, United States

Haichen Wang, Hana Dawson, Department of Medicine, Division of Neurology, Duke University, Durham, NC 27710, United States

Beilei Lei, Michael L James, Multidisciplinary Neuroprotection Laboratories, Department of Anesthesiology, Duke University, Durham, NC 27710, United States

Afoma Umeano, Department of Chemistry, Harvard University, Cambridge, MA 27710, United States

Dawn Kernagis, Department of Anesthesiology, Duke University, Durham, NC 27710, United States

Author contributions: All authors contributed to this manuscript.

Institutional review board statement: This study was approved by the Duke University Animal Care and Use Committee.

Conflict-of-interest statement: All authors have no conflicts of interest to declare.

Data sharing statement: All data and all data are deposited at Duke University in Durham, NC.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

Manuscript source: Unsolicited manuscript

Correspondence to: Michael L James, Associate Professor of Anesthesiology and Neurology, Multidisciplinary

Neuroprotection Laboratories, Department of Anesthesiology, Duke University, DUMC 3094, Durham, NC 27710, United States. [michael.james@duke.edu](mailto:michael.james@duke.edu)  
Telephone: +1-919-6816472  
Fax: +1-919-6814698

Received: June 30, 2016

Peer-review started: July 1, 2016

First decision: August 5, 2016

Revised: December 20, 2016

Accepted: January 11, 2017

Article in press: January 11, 2017

Published online: May 4, 2017

**Abstract****AIM**

To address the hypothesis that young, gonad-intact female mice have improved long-term recovery associated with decreased neuroinflammation compared to male mice.

**METHODS**

Eight to ten week-old male, female, and ovariectomized (OVX) mice underwent closed cranial impact. Gonad-intact female mice were injured only in estrus state. After injury, between group differences were assessed using complementary immunohistochemical staining for microglial cells at 1 h, mRNA polymerase chain reaction for inflammatory markers at 1 h after injury, Rotarod over days 1-7, and water maze on days 28-31 after injury.

**RESULTS**Male mice had a greater area of injury ( $P = 0.0063$ ), F4/80-positive cells ( $P = 0.032$ ), and up regulation of inflammatory genes compared to female mice. Male and OVX mice had higher mortality after injury when compared to female mice ( $P = 0.043$ ). No group

differences were demonstrated in Rotarod latencies ( $P = 0.62$ ). OVX mice demonstrated decreased water maze latencies compared to other groups ( $P = 0.049$ ).

### CONCLUSION

Differences in mortality, long-term neurological recovery, and markers of neuroinflammation exist between female and male mice after moderate traumatic brain injury (MTBI). Unexpectedly, OVX mice have decreased long term neurological function after MTBI when compared to gonad intact male and female mice. As such, it can be concluded that the presence of female gonadal hormones may influence behavioural outcomes after MTBI, though mechanisms involved are unclear.

**Key words:** Traumatic brain injury; Microglia; Functional recovery; Inflammation; Sex

© **The Author(s) 2017.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Differences in mortality, long-term neurological recovery, and markers of neuroinflammation exist between female and male mice after moderate traumatic brain injury (MTBI). Unexpectedly, ovariectomized mice have decreased long term neurological function after MTBI when compared to gonad intact male and female mice.

Umeano O, Wang H, Dawson H, Lei B, Umeano A, Kernagis D, James ML. Female gonadal hormone effects on microglial activation and functional outcomes in a mouse model of moderate traumatic brain injury. *World J Crit Care Med* 2017; 6(2): 107-115 Available from: URL: <http://www.wjgnet.com/2220-3141/full/v6/i2/107.htm> DOI: <http://dx.doi.org/10.5492/wjccm.v6.i2.107>

## INTRODUCTION

In the United States, up to 6 million people sustain head injury annually<sup>[1-3]</sup>. Traumatic brain injury (TBI) is often graded as mild, moderate, or severe based on the patient's initial level of consciousness and presenting Glasgow coma score (GCS)<sup>[4]</sup>. Mild to moderate TBI (MTBI) is the most common type and occurs from injury of minimal duration and severity<sup>[5,6]</sup>. However, physiological manifestations such as diminished cerebral blood flow, neuroinflammation, impaired neurotransmission, cerebral edema, and abnormal glucose metabolism may occur after MTBI<sup>[2,7,8]</sup>. Further, MTBI is most common in young adults, resulting in significant long-term comorbidities, such as depression, substance abuse, chronic pain, unemployment, and post-traumatic stress disorder<sup>[6,7]</sup>. Currently, no proven therapy exists for patients with MTBI.

Sex differences in recovery after TBI are largely due to female gonadal hormones decreasing acute neuroinflammation<sup>[9,10]</sup> and increasing neuronal survival<sup>[11,12]</sup>. This has resulted in progesterone moving into clinical trial

for patients with moderate to severe TBI<sup>[13]</sup>. While prior work has largely focused on models of severe TBI where neuroinflammation is most pronounced, these sex effects have not been adequately assessed in MTBI.

Thus, this study sought to assess sex differences in modifying recovery after MTBI. Specifically, the hypothesis was that young, gonad-intact female mice have improved long-term recovery associated with decreased neuroinflammation compared to male mice. Additionally, ovariectomized (OVX) mice were included in neurobehavioral outcomes to begin to model potential sex effects in "menopausal" states.

## MATERIALS AND METHODS

All experiments were approved by the Duke University Institutional Animal Care and Use Committee and were designed to minimize suffering and numbers of animals. Experimental cohorts consisted of 8-10 wk old C57BL/6J male, gonad-intact female mice, and OVX mice (Jackson Laboratories, Bar Harbor, ME). OVX surgeries were performed at Jackson Laboratories with injury performed 4-6 wk after ovariectomy. All mice were housed in groups of 5 mice/cage in a 12-h day/night light cycle for 5-7 d prior to injury. Prior to and immediately after injury, all animals were provided free access to standard laboratory rodent chow and filtered water. All observers were blinded to grouping during injury and throughout all outcomes measurements.

### Experimental groups

The following experimental groups were utilized after injury with MTBI: Group 1 - Microglial activation/macrophage recruitment - Stereology for F4/80<sup>+</sup> cells was performed in the hippocampus of 16 mice (5 male, 5 female, 3 sham female, 3 sham male) at 1 h after injury; Group 2 - Blood-brain barrier (BBB) permeability - Immunoglobulin G (IgG) staining was performed in the cerebral cortex of 16 mice (5 male, 5 female, 3 sham female, 3 sham male) at 1 h after injury; Group 3 - Inflammatory gene regulation - Reverse transcriptase polymerase chain reactions (RT-PCR) was performed on whole brain samples of 20 mice (5 sham female, 5 sham male, 5 female, 5 male) at 1 h after injury; Group 4 - Neurobehavioral Recovery - Experimental - 59 mice (22 female, 20 male, 17 OVX) were subjected to Rotarod (RR) testing over Days 1-7 and water maze (WM) testing at Days 28-31 after injury. Mortality was assessed during the 31 d of testing; Group 5 - Neurobehavioral Recovery - Sham - 25 mice (10 female, 10 male, 5 OVX) were subjected to Rotarod (RR) testing over Days 1-7 and water maze (WM) testing at Days 28-31 after injury.

### Vaginal smear

Prior to injury, female mice underwent morning vaginal smears in order to determine reproductive state<sup>[14]</sup>. Mice in the estrus stage, characterized by having a cluster of irregularly shaped, cornified squamous epithelia cells that lacked nuclei, were used in experiments. Mice in other

stages were subsequently smeared on consecutive days until they could be classified as estrus.

### **MTBI model**

This murine TBI model was adapted from a previously described model of closed cranial trauma for the rat<sup>[15-17]</sup>. After anesthesia induction with 4.6% isoflurane, the trachea was intubated and the lungs were mechanically ventilated with 1.6% isoflurane in 30% O<sub>2</sub>/70% N<sub>2</sub>. Rectal temperature was maintained at 37 °C. Mice were positioned in a stereotactic device, scalp incised, and the skull exposed. A concave 3-mm metallic disc was glued to the skull immediately caudal to bregma. A 2.0-mm-diameter pneumatic impactor (Air-Power, Inc. High Point, NC) was used to deliver a single midline impact to the disc surface. The impactor was discharged at 6.8 ± 0.2 m/s with head displacement of 3 mm. After impact, anesthesia was discontinued, the animals were allowed to recover spontaneous ventilation, and trachea was extubated. Following recovery, mice were allowed free access to food and water. Adequate MTBI was arbitrarily defined as having day 1 RR latency between 50% and 90% of baseline. Day 1 RR latency greater than 90% of baseline is indicative of inadequate injury, while Day 1 RR latency less than 50% of baseline is indicative of severe TBI. Sham mice underwent comparable anesthesia and surgical manipulation but received no cortical impact.

### **Immunohistochemistry: Microglial and IgG staining**

One hour after injury, the mice were anesthetized with 4.6% isoflurane in 30% O<sub>2</sub>/70% N<sub>2</sub> and euthanized using intracardiac perfusion with normal saline. Whole brain samples were removed, placed in formalin and stored at 4 °C. Axial sections (40 µm) were cut on a vibratome in 20-µm intervals over the rostral-caudal extent of the lesion and collected in cryoprotectant solution containing ethylene glycol, sucrose, and sodium phosphate.

To assess microglia activation/macrophage recruitment staining, F4/80 immunohistochemistry was performed. Free-floating sections were incubated in 1% H<sub>2</sub>O<sub>2</sub> for 5 min and transferred to 0.1% Saponin for 1 h. Next, sections were incubated for 30 min in 10% goat serum followed by two successive blocking steps with Avidin and Biotin for 15 min each. Monoclonal rat anti-mouse F4/80 (MCA497R; Serotec, Raleigh, NC, United States) was applied overnight at 40 °C at a dilution of 1:20000. After washing with Phosphate Buffered Saline, biotinylated goat anti-rat IgG secondary antibody (Vector Laboratories, Inc.; 1:3000) was applied for 20 min followed by avidin-biotin-peroxidase complex treatment for 12 min (ABC kit, Vector Laboratories, Inc., Burlingame, CA, United States).

For determining BBB permeability, we stained for presence of IgG, which is usually not present with an intact BBB<sup>[18]</sup>. For IgG determination, no primary antibody was used; brain slices were incubated using 1:3000 anti-mouse IgG antibody. Staining was visualized with

diaminobenzidine (Vector Laboratories, Inc. Burlingame, CA, United States). Sections were mounted onto slides and allowed to dry overnight. Following immunostaining, all sections were counterstained with hematoxylin (Fisher Scientific, Fair Lawn, NJ, United States) for 4 min. After dehydration, sections were cover slipped using Di-N-Butyle Phthalate in Xylene resin. Determination of IgG presence was determined by the area of fluorescence within the tissue samples.

### **Stereology**

Cell counting was conducted using a Nikon 218912 light microscope interfaced with the StereoInvestigator software package (MicroBrightField, Williston, VT, United States). The number of stained cells per cubic millimeter of hippocampus was estimated by the optical fractionator method. The optical fractionator is an unbiased counting method, which is independent of the size, shape, and orientation of the cells to be counted. The parameters of the fractionator sampling scheme were established in a pilot experiment and uniformly applied to all animals. Before counting, all the slides were coded to avoid experimenter bias. As determined by Stereo Investigator, we chose six sagittal sections (40 µm thick) spaced eight sections apart along the dorsal hippocampal formation by systematic random sampling. This number of sections proved sufficient to provide a coefficient of error between 0.09 and 0.11. On each section, the whole hippocampal area was delineated. For microglial quantification, the sampling grid was 399.027 (X) µm × 367.92 (Y) µm and cells were counted within a probe volume defined by the counting frame (50 µm × 50 µm) and the dissector height (11 µm). Only cells within the counting frame or overlapping the right or superior border of the counting frame, and for which nuclei came into focus while focusing down the dissector height, were counted. The total number of F4/80 cells was calculated per hippocampal volume of 1920 µm thickness<sup>[19,20]</sup>.

### **Ribonucleic acid extraction and RT-PCR**

Frozen, pulverized whole brain tissue was processed for ribonucleic acid (RNA) extraction at 1 h after injury. RNA quantity and quality were assessed with the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Inc., Wilmington, DE) and by agarose gel electrophoresis. Only samples with a 260/280 ratio between 1.9-2.1, and a 260/230 ratio greater than 2.0, were further processed. First strand complementary deoxyribonucleic acid (cDNA) was generated from 2 µg total RNA using the RT<sup>2</sup> First strand kit (SABiosciences, Frederick, MD, United States) according to the manufacturer's instructions. Gene expression was measured using the Mouse Nuclear Factor kappa B (NFκB) targeted PCR Array (SABiosciences), which profiles the expression of 84 genes related to the NFκB pathway. RT-PCR was performed according to manufacturer's instructions using the 384-well plate format (4 samples, 96 wells per sample). One sample from each experimental group was run per plate to

minimize potential batch effect between RT-PCR runs. Quality of the cDNA and PCR efficiency was verified by housekeeping genes and RT-PCR controls included in the PCR Array.

### Gene expression data analysis

Raw RT-PCR data was analyzed using the Web-Based PCR Array Data Analysis software (SABiosciences) and Microsoft Excel (Microsoft, Redmond, WA). The difference between the sequences of interest and the reference sequence ( $\Delta C_t$ ) values, the differences between the experimental and control sequences of interest ( $\Delta\Delta C_t$ ), and the based fold-change were calculated from raw threshold cycle data, using beta-actin and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as internal standards for normalization.

### Rotarod testing

An automated RR (Ugo Basile, Comerio, Italy) was used to assess vestibulomotor function<sup>[15,21]</sup>. On the day prior to injury, mice underwent a conditioning trial at a set rotational speed for 60 s and then three additional trials with an accelerating rotational speed. The average time to fall from the rotating cylinder in the latter three trials was recorded as baseline latency. On days 1, 3, 5, and 7 post-MTBI, the mice had three consecutive trials with accelerating rotational speed (inter-trial interval = 15 min). The average latency to fall from the rod was recorded. Mice unable to grasp the rotating rod were given a latency value of 0 s. Test was automatically suspended after 600 s of running.

### Water maze testing

Based on prior data<sup>[15,22]</sup>, at 28 d after injury an aluminium pool (105 cm in diameter, 60 cm in depth) was painted black and filled to 17 cm with water (25 °C–27 °C, opacified with powdered milk). The maze was kept in a room dedicated to behavioural testing with light, sound, and visual cues held constant. The goal was a hidden plastic platform, 7.5 cm in diameter, submerged 1 cm below the water surface. Mice were tested for 4 consecutive days with 4 trials per day (inter-trial interval = 1 h). Mice were placed in one of four different quadrants for each trial. Starting quadrants were randomly defined each day. Mice were allowed to search for the platform for a maximum of 90 s at which time the mice were guided to the platform. Mice remained on the platform for 5 s. The mice were kept in heated cages between trials. Our predefined surrogate marker of behavioural learning was water maze latency times, *i.e.*, the time to find the platform and swimming speed were recorded by a computerized video tracking system (Ethovision 2.2.14, Noldus Information Technology, Leesburg, VA).

### Statistical analysis

Parametric analyses were performed on all data sets. Mortality was analysed using the  $\chi^2$  test. RR and WM latencies were compared with repeated measures

analysis of variance (ANOVA) with time as the repeated variable and using Dunnett's method to correct for multiple comparisons. Stereological analysis results, quantitative PCR results, F4/80 stains and BBB permeability were analysed with student's *t*-test. Statistical significance was assumed with  $P < 0.05$ . All values were expressed as mean  $\pm$  (standard error of the mean) SEM and were performed on JMP (v7.0.1, SAS, Cary, NC).

## RESULTS

### Immunohistochemical analysis

Tissue sections of injured area were collected in a standardized fashion. The entire Area of IgG stained brain was greater in male compared to female mice at 1 h after MTBI (male vs female: 32.09 mm<sup>2</sup> + 26.82 vs 26.64 mm<sup>2</sup> + 26.04,  $P = 0.006$ ). Further, IgG stained brain area was greater in MTBI male compared to sham male mice (32.09 mm<sup>2</sup> + 26.82 vs 3.20 mm<sup>2</sup> + 1.70;  $P = 0.004$ ). F4/80-positive cells were greatest in MTBI male mice compared to MTBI female, sham male, and sham female mice at 1 h after injury (respectively: 0.036 cells/mm<sup>3</sup> + 0.02, vs 0.021 cells/mm<sup>3</sup> + 0.01, vs 0.006 cells/mm<sup>3</sup> + 0.001, vs 0.011 cells/mm<sup>3</sup> + 0.001,  $P = 0.032$ ).

### Gene expression


Using focused arrays, multiple genes were differentially expressed between sham male, sham female, male, and female mice at 1 h after MTBI (Table 1). Using relative expression of gene activation [fold change (FC)] of injured vs sham animals, MTBI in male mice was associated with greater activation of inflammatory genes tumor necrosis factor (TNF- $\alpha$ ; FC = 30.257, SD = 0.287), interleukin (IL)-1a (FC = 11.356, SD = 0.252), IL-6 (FC = 4.769, SD = 0.379), and C-X-C motif chemokine (CXCL)-10 (FC = 9.327, SD = 0.172). Compared to female shams, MTBI in female mice was also associated with greater activation of inflammatory genes TNF- $\alpha$  (FC = 10.856, SD = 0.082), IL-6 (FC = 2.952, SD = 0.177), IL-1a (FC = 8.807, SD = 0.109), and CXCL-10 (FC = 5.369, SD = 0.091). When comparing male to female mice after MTBI, inflammatory genes TNF, CXCL-10, and IL-6 had greater expression in male mice ( $R = 2.786, 1.737, \text{ and } 1.614$ , respectively, Figure 1).

### Neurobehavioral testing

Of the total 59 mice that were injured, 49 survived [20 of 22 (91%) female, 17 of 20 (85%) male, and 12 of 17 (71%) OVX;  $P = 0.043$ ]. Of the 49 surviving mice, 46 were adequately injured to fulfill the definition of MTBI (19 of 20 female mice, 17 of 17 male mice, and 10 of 12 OVX mice). All surviving animals meeting criteria for MTBI were analyzed (Figure 2). No differences in RR latencies between groups over the first 7 d after injury were found ( $P = 0.62$ ). OVX mice demonstrated longer WM latencies over 28–31 d after injury ( $P = 0.049$ ). While overall latencies were not different between male and female mice after MTBI, the difference in WM latencies between the first day and last day of testing was greater for

**Table 1 Significant inflammatory genes in polymerase chain reaction analysis**

Gene	Fold change males	Stdev males	Fold change females	Stdev females
<i>Ccl22</i>	-4.379926621	0.219833970	-1.808791666	0.07209482
<i>Birc3</i>	2.424699902	0.347280537	6.393699028	0.04457375
<i>Fasl</i>	1.282942934	0.586876307	3.595274272	0.15614853
<i>Cxcl3</i>	1.423783611	0.443555855	4.738673464	0.13768048
<i>Il12b</i>	1.887247846	0.153962747	6.969172751	0.07141293
<i>Csf2rb</i>	-2.029836886	0.504576222	2.002641941	0.04827339
<i>C4a</i>	-5.138319145	0.111529531	2.068435781	0.09152752
<i>Ccl12</i>	1.004666934	0.407715962	12.36078104	0.06841648
<i>Il1a</i>	11.35623576	0.252021657	8.806597114	0.10903830
<i>Ltb</i>	1.883908897	0.112197741	1.410932285	0.03827274
<i>Sele</i>	2.645681512	0.175734401	1.81041664	0.07499996
<i>Il1b</i>	15.62412184	0.259189696	10.81446519	0.08663391
<i>Cxcl10</i>	9.327227458	0.172197097	5.36922489	0.09101903
<i>Il6</i>	4.768742556	0.379381266	2.952867421	0.17661706
<i>Icam1</i>	3.304520395	0.364423780	1.778613038	0.12022752
<i>Cxcl9</i>	1.25441829	0.250388088	-1.750912312	0.07922075
<i>Tnf</i>	30.25742899	0.286872446	10.85969992	0.08157591
<i>Lta</i>	-1.18052165	0.435317336	-22.22152490	0.08186537
<i>Relb</i>	2.632882795	0.110186834	-4.717581418	0.11019118
<i>Ifng</i>	2.706432675	0.341618642	-2.698000440	0.12030042
<i>Ifnb1</i>	-1.300071257	0.147446990	-8.018307062	0.12328928
<i>Adm</i>	4.645463022	0.411030849	-1.324109025	0.10189112
<i>Agt</i>	1.850525351	0.353829239	-2.447168033	0.06028075
<i>Csf2</i>	3.379073426	0.166397911	-1.105541488	0.07037648
<i>Myd88</i>	3.113516447	0.407823225	1.013600401	0.05586930



**Figure 1 Ratio of inflammatory gene expression in experimental male and female mice.** Since the ratio is a male/female value, genes with a ratio of less than one are genes that are less expressed in male mice and genes with ratios of greater than two are more expressed in male mice. Genes with ratios close to one are evenly expressed between both sexes.

female mice (M = 32.69 s) than male mice (M = 26.15 s;  $P = 0.034$ ), which may serve as a corollary marker for learning. Sham data for male, female and OVX mice (Figure 3) show no sex interaction between the groups for water maze latencies.


## DISCUSSION

At one hour after MTBI, female mice demonstrate decreased BBB permeability (IgG), microglial activation/macrophage recruitment (F4/80), and inflammatory gene expression (RT-PCR) compared to male mice. Concurrently, male mice demonstrate greater mortality than female mice after MTBI. Absence of female gonadal


hormones (OVX) results in greater mortality and worse long-term neurobehavioral recovery.

While published data from preclinical models of severe TBI are ubiquitous, modeling of MTBI may be under-represented. In the United States, MTBI represents 75% of the total TBI cases<sup>[23]</sup>. Further, MTBI may result in long-term disability in 21% of cases<sup>[24,25]</sup>. In light of clinical trials with progesterone for moderate to severe TBI, potential effects of sex and female gonadal hormones in modifying outcome after MTBI should be investigated.

MTBI has been previously reproduced through pre-clinical injury modeling<sup>[26]</sup>. In the current model, MTBI was defined as an injury producing Day 1 RR latency between 50% and 90% of the baseline. While somewhat



**Figure 2 Short- and long-term neurobehavioral measurements after mild traumatic injury in mice.** Rotarod latencies (A) were not different over Days 1-7 after moderate traumatic brain injury (MTBI) ( $P = 0.62$ ; ANOVA). Significant water maze (WM) latencies (B) differences were demonstrated between groups over Days 28-31 after MTBI. WM latencies did not differ between male and female mice after MTBI, but ovariectomized mice demonstrated longer latencies over the testing period ( $P = 0.04$ ; ANOVA).



**Figure 3 Water maze latencies for sham male, female and ovariectomized mice.** No sex interaction was seen between male, female, and ovariectomized (OVX) mice over Days 28-31 after moderate traumatic brain injury, thus no significant sex differences are observed for shams.

high mortality. Further, post-injury Day 1 RR latencies were similar across all groups. Thus, the present definition of MTBI is an acceptable approximation of MTBI outcome in patients while at the same time allowing for between groups comparisons.

Data presented here demonstrate that the pathophysiology of MTBI may be quite different than that involved in severe TBI. A strong sex effect on recovery has been previously demonstrated in preclinical models of severe TBI<sup>[27]</sup>. In addition, gonadal hormones, particularly progesterone, have repeatedly demonstrated improvement in outcome in models of severe TBI<sup>[12,28,29]</sup>. Recently, progesterone has been used in combination with nicotinamide and interest has increased for estrogen as neuroprotectants against severe TBI<sup>[30,31]</sup>. However, in our model, sex may not be a major modifier of neurobehavioral outcome after MTBI. This finding may represent the lack of sustained injury after MTBI and the sensitivities of the RR and WM tests for uncovering mild to moderate injury. Perhaps new behavioral tests should be defined for MTBI. An excellent review of the development of various TBI models was recently published<sup>[32]</sup>, including

arbitrary, this definition allows noticeable neurobehavioral impairment but falls short of severe injury and associated

preclinical models that may represent MTBI. In fact, MTBI clearly differs from other more severe injury models of TBI in that immediate neurological deficits are not present while profound histopathological evidence exists for brain injury<sup>[33]</sup>.

Interestingly, the removal of female gonadal hormones, as seen in OVX, worsened long-term neurobehavioral outcomes in this model of MTBI more so than the complete absence of female sex hormones as seen with male mice. Underlying mechanisms for this finding remain unclear in MTBI, but this theme has been echoed in other neural injury models<sup>[30,31]</sup>. Thus, future investigation should include exogenous administration of female gonadal hormones (both estrogen and progesterone) in an attempt to reverse these detrimental effects after MTBI.

Sex differences in BBB permeability after MTBI suggest that vascularity and vasculogenesis may be influenced by gonadal hormones<sup>[32,33]</sup>. Moreover, estrogens have been shown to be vasculogenic inducers through associations with endothelial progenitor cells<sup>[32,34,35]</sup>. Thus, it can be postulated that gonad-intact female mice may demonstrate increased vasculogenesis after MTBI due to the presence of female gonadal hormones, when compared to male and OVX mice.

There are several limitations to this study that should be addressed. First, neither microglial activation nor BBB permeability was determined for OVX-female mice. The primary hypothesis was that young, gonad-intact female mice have improved long-term recovery associated with decreased neuroinflammation compared to male mice<sup>[36-39]</sup>. The addition of (OVX) mice occurred to begin to model potential sex effects in "menopausal" states. It is now clear that future studies should compare OVX, male, and gonad-intact female mice when assessing the role of gonadal hormones and sex differences after MTBI. Second, the effects of TBI-induced pituitary dysfunction, could be a potential confounding factor. Clinical and experimental studies clearly demonstrated that significant proportion of patients develop hypopituitarism after TBI with gonadotropin deficiency being one of the more common deficiencies<sup>[40]</sup>. Result in follicular stimulating hormone and luteinizing hormone deficiencies result in decreased circulating estrogen and progesterone. Thus, pituitary effects alone may explain the heterogeneity in the outcome after TBI in young female rats. In addition, mice excluded due to insufficient injury were dissimilar across groups [2 of 17 OVX (11%), 1 of 22 males (5%), and 0 females (0%) were excluded]. While this may be the result of model variability, future work should examine the effects of gonadal hormones across the spectrum of TBI severity. Also, the interaction of age and sex was not examined in this study. Further, this study did not evaluate multiple isolated MTBI injuries, which may be more applicable to MTBI in humans with accumulation of injury over time. Finally, as previously mentioned, RR and WM may not be the most sensitive assessments for subtle neurocognitive impairment seen after MTBI. However, because these metrics were

validated in previous studies<sup>[15,41-45]</sup>, we consider them appropriate for use in the present study.

While these limitations exist, there remain compelling clinical implications for the current findings. First, associations between loss of female gonadal hormones and worse long-term neurobehavioral outcomes have potential ramifications for risk stratification in postmenopausal women that sustain MTBI. Second, demonstration that sex affects recovery after MTBI differently than in severe TBI may influence future investigations of potential targets for therapeutic development and require thoughtful consideration during clinical trial design. Finally, lack of sex differences in recovery after MTBI may demonstrate the resiliency of the young brain to mild/moderate injury. Exploration of the mechanisms, especially when contrasted with the aged brain, may bring translatable ideas into clinical research.

In conclusion, female sex is associated with decreased BBB permeability, markers of neuroinflammation, and mortality. Further, loss of female gonadal hormones is associated with worse long-term neurobehavioral recovery after MTBI. Future research should define sex-specific mechanisms of neuroinflammation after MTBI and the role of female gonadal hormones in potentiating recovery.

## COMMENTS

### Background

Sex differences in mild traumatic brain injury (TBI) are understudied, but prior studies in other forms of brain injury have found distinct sex differences. Further, pathophysiologic mechanisms for sex differences are not completely understood.

### Research frontiers

Understanding relevant pathophysiology of sex differences after TBI will alter treatment choices and development for patients.

### Innovations and breakthroughs

A new model of mild TBI is clinically relevant in that it mimics the form of injury that the majority of patients experience. Further, increased understanding of sex differences in this form of TBI begins to alter the way clinicians approach these patients.

### Applications

Future research should define sex-specific mechanisms of neuroinflammation after MTBI and the role of female gonadal hormones in potentiating recovery.

### Peer-review

The manuscript is interesting.

## REFERENCES

- 1 **Heegaard W**, Biros M. Traumatic brain injury. *Emerg Med Clin North Am* 2007; **25**: 655-678, viii [PMID: 17826211 DOI: 10.1016/j.emc.2007.07.001]
- 2 **Ghajar J**. Traumatic brain injury. *Lancet* 2000; **356**: 923-929 [PMID: 11036909 DOI: 10.1016/S0140-6736(00)02689-1]
- 3 **Töro K**, Szilvia F, György D, Pauliukevicius A, Caplinskiene M, Raudys R, Lepik D, Tuusov J, Vali M. Fatal traffic injuries among children and adolescents in three cities (capital Budapest, Vilnius, and Tallinn). *J Forensic Sci* 2011; **56**: 617-620 [PMID: 21352227 DOI: 10.1111/j.1556-4029.2010.01674.x]
- 4 **Foreman BP**, Caesar RR, Parks J, Madden C, Gentilello LM, Shafi

- S, Carlile MC, Harper CR, Diaz-Arrastia RR. Usefulness of the abbreviated injury score and the injury severity score in comparison to the Glasgow Coma Scale in predicting outcome after traumatic brain injury. *J Trauma* 2007; **62**: 946-950 [PMID: 17426553 DOI: 10.1097/01.ta.0000229796.14717.3a]
- 5 **Powell JW**, Barber-Foss KD. Traumatic brain injury in high school athletes. *JAMA* 1999; **282**: 958-963 [PMID: 10485681 DOI: 10.1001/jama.282.10.958]
- 6 **Hoge CW**, McGurk D, Thomas JL, Cox AL, Engel CC, Castro CA. Mild traumatic brain injury in U.S. Soldiers returning from Iraq. *N Engl J Med* 2008; **358**: 453-463 [PMID: 18234750 DOI: 10.1056/NEJMoa072972]
- 7 **Iverson GL**. Outcome from mild traumatic brain injury. *Curr Opin Psychiatry* 2005; **18**: 301-317 [PMID: 16639155 DOI: 10.1097/01.yco.0000165601.29047.ae]
- 8 **Vos PE**. Biomarkers of focal and diffuse traumatic brain injury. *Crit Care* 2011; **15**: 183 [PMID: 21955684 DOI: 10.1186/cc10290]
- 9 **Nilsson BO**. Modulation of the inflammatory response by estrogens with focus on the endothelium and its interactions with leukocytes. *Inflamm Res* 2007; **56**: 269-273 [PMID: 17659431 DOI: 10.1007/s00011-007-6198-z]
- 10 **Drew PD**, Chavis JA. Female sex steroids: effects upon microglial cell activation. *J Neuroimmunol* 2000; **111**: 77-85 [PMID: 11063824 DOI: 10.1016/S0165-5728(00)00386-6]
- 11 **Dimayuga FO**, Reed JL, Carnero GA, Wang C, Dimayuga ER, Dimayuga VM, Perger A, Wilson ME, Keller JN, Bruce-Keller AJ. Estrogen and brain inflammation: effects on microglial expression of MHC, costimulatory molecules and cytokines. *J Neuroimmunol* 2005; **161**: 123-136 [PMID: 15748951 DOI: 10.1016/j.jneuroim.2004.12.016]
- 12 **Pettus EH**, Wright DW, Stein DG, Hoffman SW. Progesterone treatment inhibits the inflammatory agents that accompany traumatic brain injury. *Brain Res* 2005; **1049**: 112-119 [PMID: 15932748 DOI: 10.1016/j.brainres.2005.05.004]
- 13 **Wright DW**, Kellermann AL, Hertzberg VS, Clark PL, Frankel M, Goldstein FC, Salomone JP, Dent LL, Harris OA, Ander DS, Lowery DW, Patel MM, Denson DD, Gordon AB, Wald MM, Gupta S, Hoffman SW, Stein DG. ProTECT: a randomized clinical trial of progesterone for acute traumatic brain injury. *Ann Emerg Med* 2007; **49**: 391-402, 402.e1-2 [PMID: 17011666]
- 14 **Caligioni CS**. Assessing reproductive status/stages in mice. *Curr Protoc Neurosci* 2009; **Appendix 4**: Appendix 4I [PMID: 19575469 DOI: 10.1016/j.anememergmed.2006.07.932]
- 15 **Lynch JR**, Wang H, Mace B, Leinenweber S, Warner DS, Bennett ER, Vitek MP, McKenna S, Laskowitz DT. A novel therapeutic derived from apolipoprotein E reduces brain inflammation and improves outcome after closed head injury. *Exp Neurol* 2005; **192**: 109-116 [PMID: 15698624 DOI: 10.1016/j.expneurol.2004.11.014]
- 16 **Lynch JR**, Wang H, McGirt MJ, Floyd J, Friedman AH, Coon AL, Blessing R, Alexander MJ, Graffagnino C, Warner DS, Laskowitz DT. Simvastatin reduces vasospasm after aneurysmal subarachnoid hemorrhage: results of a pilot randomized clinical trial. *Stroke* 2005; **36**: 2024-2026 [PMID: 16051891 DOI: 10.1161/01.STR.0000177879.11607.10]
- 17 **Marmarou A**, Foda MA, van den Brink W, Campbell J, Kita H, Demetriadou K. A new model of diffuse brain injury in rats. Part I: Pathophysiology and biomechanics. *J Neurosurg* 1994; **80**: 291-300 [PMID: 8283269 DOI: 10.3171/jns.1994.80.2.0291]
- 18 **Triguero D**, Buciak JB, Yang J, Pardridge WM. Blood-brain barrier transport of cationized immunoglobulin G: enhanced delivery compared to native protein. *Proc Natl Acad Sci USA* 1989; **86**: 4761-4765 [PMID: 2734318 DOI: 10.1073/pnas.86.12.4761]
- 19 **Indraswari F**, Wang H, Lei B, James ML, Kernagis D, Warner DS, Dawson HN, Laskowitz DT. Statins improve outcome in murine models of intracranial hemorrhage and traumatic brain injury: a translational approach. *J Neurotrauma* 2012; **29**: 1388-1400 [PMID: 22233347 DOI: 10.1089/neu.2011.2117]
- 20 **Lei B**, Dawson HN, Roulhac-Wilson B, Wang H, Laskowitz DT, James ML. Tumor necrosis factor  $\alpha$  antagonism improves neurological recovery in murine intracerebral hemorrhage. *J Neuroinflammation* 2013; **10**: 103 [PMID: 23962089 DOI: 10.1186/1742-2094-10-103]
- 21 **Hamm RJ**, Pike BR, O'Dell DM, Lyeth BG, Jenkins LW. The rotarod test: an evaluation of its effectiveness in assessing motor deficits following traumatic brain injury. *J Neurotrauma* 1994; **11**: 187-196 [PMID: 7932797 DOI: 10.1089/neu.1994.11.187]
- 22 **Morris R**. Developments of a water-maze procedure for studying spatial learning in the rat. *J Neurosci Methods* 1984; **11**: 47-60 [PMID: 6471907 DOI: 10.1016/0165-0270(84)90007-4]
- 23 **Bruns JJ**, Jagoda AS. Mild traumatic brain injury. *Mt Sinai J Med* 2009; **76**: 129-137 [PMID: 19306376 DOI: 10.1002/msj.20101]
- 24 **Thornhill S**, Teasdale GM, Murray GD, McEwen J, Roy CW, Penny KI. Disability in young people and adults one year after head injury: prospective cohort study. *BMJ* 2000; **320**: 1631-1635 [PMID: 10856063 DOI: 10.1136/bmj.320.7250.1631]
- 25 **Carroll LJ**, Cassidy JD, Peloso PM, Borg J, von Holst H, Holm L, Paniak C, Pépin M. Prognosis for mild traumatic brain injury: results of the WHO Collaborating Centre Task Force on Mild Traumatic Brain Injury. *J Rehabil Med* 2004; **36**: 84-105 [PMID: 15083873 DOI: 10.1080/16501960410023859]
- 26 **Foda MA**, Marmarou A. A new model of diffuse brain injury in rats. Part II: Morphological characterization. *J Neurosurg* 1994; **80**: 301-313 [PMID: 8283270 DOI: 10.3171/jns.1994.80.2.0301]
- 27 **Stein DG**. Brain damage, sex hormones and recovery: a new role for progesterone and estrogen? *Trends Neurosci* 2001; **24**: 386-391 [PMID: 11410269 DOI: 10.1016/S0166-2236(00)01821-X]
- 28 **Stein DG**. Progesterone exerts neuroprotective effects after brain injury. *Brain Res Rev* 2008; **57**: 386-397 [PMID: 17826842 DOI: 10.1016/j.brainresrev.2007.06.012]
- 29 **He J**, Evans CO, Hoffman SW, Oyesiku NM, Stein DG. Progesterone and allopregnanolone reduce inflammatory cytokines after traumatic brain injury. *Exp Neurol* 2004; **189**: 404-412 [PMID: 15380490 DOI: 10.1016/j.expneurol.2004.06.008]
- 30 **Veiga S**, Melcangi RC, DonCarlos LL, Garcia-Segura LM, Azcoitia I. Sex hormones and brain aging. *Exp Gerontol* 2004; **39**: 1623-1631 [PMID: 15582278 DOI: 10.1016/j.exger.2004.05.008]
- 31 **Peterson TC**, Hoane MR, McConomy KS, Farin FM, Bammler TK, MacDonald JW, Kantor ED, Anderson GD. A Combination Therapy of Nicotinamide and Progesterone Improves Functional Recovery following Traumatic Brain Injury. *J Neurotrauma* 2015; **32**: 765-779 [PMID: 25313690 DOI: 10.1089/neu.2014.3530]
- 32 **Day NL**, Floyd CL, D'Alessandro TL, Hubbard WJ, Chaudry IH. 17 $\beta$ -estradiol confers protection after traumatic brain injury in the rat and involves activation of G protein-coupled estrogen receptor 1. *J Neurotrauma* 2013; **30**: 1531-1541 [PMID: 23659385 DOI: 10.1089/neu.2013.2854]
- 33 **Povlishock J**. The History and Evolution of Experimental Traumatic Brain Injury Models. *Methods Mol Biol* 2016; **1462**: 3-7 [PMID: 27604709 DOI: 10.1007/978-1-4939-3816-2\_1]
- 34 **Turner RC**, VanGilder RL, Naser ZJ, Lucke-Wold BP, Bailes JE, Matsumoto RR, Huber JD, Rosen CL. Elucidating the severity of preclinical traumatic brain injury models: a role for functional assessment? *Neurosurgery* 2014; **74**: 382-394; discussion 394 [PMID: 24448183 DOI: 10.1227/NEU.0000000000000292]
- 35 **Alkayed NJ**, Harukuni I, Kimes AS, London ED, Traystman RJ, Hurn PD. Gender-linked brain injury in experimental stroke. *Stroke* 1998; **29**: 159-165; discussion 166 [PMID: 9445346 DOI: 10.1161/01.STR.29.1.159]
- 36 **Fadini GP**, de Kreutzenberg S, Albiero M, Coracina A, Pagnin E, Baesso I, Cignarella A, Bolego C, Plebani M, Nardelli GB, Sartore S, Agostini C, Avogaro A. Gender differences in endothelial progenitor cells and cardiovascular risk profile: the role of female estrogens. *Arterioscler Thromb Vasc Biol* 2008; **28**: 997-1004 [PMID: 18276910 DOI: 10.1161/ATVBAHA.107.159558]
- 37 **Jujo K**, Li M, Losordo DW. Endothelial progenitor cells in neovascularization of infarcted myocardium. *J Mol Cell Cardiol* 2008; **45**: 530-544 [PMID: 18755197 DOI: 10.1016/j.yjmcc.2008.08.003]
- 38 **Hoetzer GL**, MacEneaney OJ, Irminger HM, Keith R, Van Guildler GP, Stauffer BL, DeSouza CA. Gender differences in circulating endothelial progenitor cell colony-forming capacity and migratory activity in middle-aged adults. *Am J Cardiol* 2007; **99**: 46-48 [PMID:

- 17196460 DOI: 10.1016/j.amjcard.2006.07.061]
- 39 **Iwakura A**, Luedemann C, Shastry S, Hanley A, Kearney M, Aikawa R, Isner JM, Asahara T, Losordo DW. Estrogen-mediated, endothelial nitric oxide synthase-dependent mobilization of bone marrow-derived endothelial progenitor cells contributes to reendothelialization after arterial injury. *Circulation* 2003; **108**: 3115-3121 [PMID: 14676142 DOI: 10.1161/01.CIR.0000106906.56972.83]
- 40 **Tanriverdi F**, Schneider HJ, Aimaretti G, Masel BE, Casanueva FF, Kelestimur F. Pituitary dysfunction after traumatic brain injury: a clinical and pathophysiological approach. *Endocr Rev* 2015; **36**: 305-342 [PMID: 25950715 DOI: 10.1210/er.2014-1065]
- 41 **James ML**, Wang H, Venkatraman T, Song P, Lascola CD, Laskowitz DT. Brain natriuretic peptide improves long-term functional recovery after acute CNS injury in mice. *J Neurotrauma* 2010; **27**: 217-228 [PMID: 19803787 DOI: 10.1089/neu.2009.1022]
- 42 **Laskowitz DT**, McKenna SE, Song P, Wang H, Durham L, Yeung N, Christensen D, Vitek MP. COG1410, a novel apolipoprotein E-based peptide, improves functional recovery in a murine model of traumatic brain injury. *J Neurotrauma* 2007; **24**: 1093-1107 [PMID: 17610350 DOI: 10.1089/neu.2006.0192]
- 43 **James ML**, Sullivan PM, Lascola CD, Vitek MP, Laskowitz DT. Pharmacogenomic effects of apolipoprotein e on intracerebral hemorrhage. *Stroke* 2009; **40**: 632-639 [PMID: 19109539 DOI: 10.1161/STROKEAHA.108.530402]
- 44 **Wang H**, Lynch JR, Song P, Yang HJ, Yates RB, Mace B, Warner DS, Guyton JR, Laskowitz DT. Simvastatin and atorvastatin improve behavioral outcome, reduce hippocampal degeneration, and improve cerebral blood flow after experimental traumatic brain injury. *Exp Neurol* 2007; **206**: 59-69 [PMID: 17521631 DOI: 10.1016/j.expneurol.2007.03.031]
- 45 **Wang H**, Gao J, Lassiter TF, McDonagh DL, Sheng H, Warner DS, Lynch JR, Laskowitz DT. Levetiracetam is neuroprotective in murine models of closed head injury and subarachnoid hemorrhage. *Neurocrit Care* 2006; **5**: 71-78 [PMID: 16960300 DOI: 10.1385/NCC.5:1:71]

**P- Reviewer:** Soriano-Ursua MA, Tanriverdi F **S- Editor:** Ji FF  
**L- Editor:** A **E- Editor:** Lu YJ





Published by **Baishideng Publishing Group Inc**  
7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA  
Telephone: +1-925-223-8242  
Fax: +1-925-223-8243  
E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
Help Desk: <http://www.f6publishing.com/helpdesk>  
<http://www.wjgnet.com>

